Abstract
Dupilumab is a monoclonal antibody against IL-4Ra, approved for treatment of multiple atopic diseases, including asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupilumab clinical trials showed low discontinuation rates. As dupilumab targets key mechanisms implicated in multiple atopic comorbidities, there exists a need to understand how allergic comorbidities affect dupilumab persistence when prescribed for indications of asthma and CRSwNP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
